Oncology Times (@oncologytimes) 's Twitter Profile
Oncology Times

@oncologytimes

Reporting essential clinical news w/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology/hematology

ID: 19495715

linkhttp://oncology-times.com calendar_today25-01-2009 17:22:19

30,30K Tweet

53,53K Followers

8,8K Following

Oncology Times (@oncologytimes) 's Twitter Profile Photo
Oncology Times
@oncologytimes

2 years ago

Researchers observed no significant difference between high-dose intravenous methotrexate and intrathecal methotrexate for CNS relapse prophylaxis among newly diagnosed, high-risk #DLBCL patients, according to findings presented during #EHA23. ow.ly/iMBe50QccH1

Researchers observed no significant difference between high-dose intravenous methotrexate and intrathecal methotrexate for CNS relapse prophylaxis among newly diagnosed, high-risk #DLBCL patients, according to findings presented during #EHA23. ow.ly/iMBe50QccH1